CRSP (CRISPR Therapeutics AG) EBIT per Share : $-5.56 (TTM As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is CRISPR Therapeutics AG EBIT per Share?

CRISPR Therapeutics AG's EBIT per Share for the three months ended in Mar. 2025 was $-1.73. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $-5.56.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for CRISPR Therapeutics AG's EBIT per Share or its related term are showing as below:

During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of CRISPR Therapeutics AG was 19.40% per year. The lowest was -92.60% per year. And the median was -52.50% per year.

CRSP's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 9.1
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

CRISPR Therapeutics AG's EBIT for the three months ended in Mar. 2025 was $-148.42 Mil.

CRISPR Therapeutics AG EBIT per Share Historical Data

The historical data trend for CRISPR Therapeutics AG's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CRISPR Therapeutics AG EBIT per Share Chart

CRISPR Therapeutics AG Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT per Share

Get a 7-Day Free Trial

-5.37

4.65

-8.66

-2.81

-5.53

CRISPR Therapeutics AG Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EBIT per Share	Get a 7-Day Free Trial															-1.72	-1.78	-1.29	-0.76	-1.73

CRISPR Therapeutics AG EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

CRISPR Therapeutics AG's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

	EBIT per Share		(A: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-466.566	/	84.359
=	-5.53

CRISPR Therapeutics AG's EBIT per Share for the quarter that ended in Mar. 2025 is calculated as

	EBIT per Share		(Q: Mar. 2025 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-148.424	/	85.939
=	-1.73

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.56

CRISPR Therapeutics AG (NAS:CRSP) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

CRISPR Therapeutics AG EBIT per Share Related Terms

Thank you for viewing the detailed overview of CRISPR Therapeutics AG's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

CRISPR Therapeutics AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (NAS:CRSP) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

CRSP:Mexico 0VRQ:UK 1CG:Germany

Address

Baarerstrasse 14, Zug, CHE, CH-6300

Website

https://www.crisprtx.com

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Executives

Raju Prasad	officer: Chief Financial Officer	CRISPR THERAPEUTICS, INC., 105 W FIRST STREET, BOSTON MA 02127
Samarth Kulkarni	officer: Chief Business Officer	C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
James R. Kasinger	officer: General Counsel and Secretary	C/O CRISPR THERAPEUTICS, INC., 610 MAIN STREET, CAMBRIDGE MA 02139
John Greene	director	51 LIME STREET, LONDON X0 EC3M 7DQ
Phuong Khanh Morrow	officer: Chief Medical Officer	C/O CRISPR THERAPEUTICS, 610 MAIN STREET, CAMBRIDGE MA 02139
Maria Fardis	director	C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Brendan Smith	officer: Chief Financial Officer	29 HARTWELL AVENUE, LEXINGTON MA 02421
Michael John Tomsicek	officer: Chief Financial Officer	28 OVERLOOK DRIVE, BEDFORD MA 01730
Bolzon Bradley J Phd	director	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Rodger Novak	director, officer: Chief Executive Officer	C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
Harold Edward Fleming	director	C/O CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139
Lawrence Otto Klein	officer: Chief Business Officer	C/O CRISPR THERAPEUTICS AG, 610 MAIN STREET 7TH FLOOR, CAMBRIDGE MA 02139
Tony W Ho	officer: See Remarks	CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139
Douglas A Treco	director	87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Pablo J Cagnoni	director	ONYX PHARMACEUTICALS, INC., 249 E. GRAND AVE., SOUTH SAN FRANCISCO CA 94080